GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » CureVac NV (LTS:0A9E) » Definitions » Institutional Ownership

CureVac NV (LTS:0A9E) Institutional Ownership : 2.02% (As of Apr. 30, 2025)


View and export this data going back to 2021. Start your Free Trial

What is CureVac NV Institutional Ownership?

Institutional ownership is the percentage of shares that are owned by institutions out of the total shares outstanding. As of today, CureVac NV's institutional ownership is 2.02%.

Insider Ownership is the percentage of shares that are owned by company insiders relative to the total shares outstanding. As of today, CureVac NV's Insider Ownership is 0.00%.

Float Percentage Of Total Shares Outstanding is the percentage of float shares relative to the total shares outstanding. As of today, CureVac NV's Float Percentage Of Total Shares Outstanding is 49.93%.


CureVac NV Institutional Ownership Historical Data

The historical data trend for CureVac NV's Institutional Ownership can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

CureVac NV Institutional Ownership Chart

CureVac NV Historical Data

The historical data trend for CureVac NV can be seen below:

2024-06-30 2024-07-31 2024-08-31 2024-09-30 2024-10-31 2024-11-30 2024-12-31 2025-01-31 2025-02-28 2025-03-31
Institutional Ownership 2.70 2.32 2.31 2.17 2.05 2.09 2.12 2.09 2.03 2.02

CureVac NV Institutional Ownership Calculation

The percentage of shares that are owned by institutions out of the total shares outstanding.


CureVac NV Business Description

Traded in Other Exchanges
Address
Friedrich-Miescher-Strasse 15, Tubingen, BW, DEU, 72076
CureVac NV is a biopharmaceutical company headquartered in Germany that is developing a new class of transformative medicines based on messenger ribonucleic acid (mRNA) that has the potential to improve the lives of people. CureVac had a collaboration with GSK to develop second-generation seasonal influenza and COVID-19 vaccines and an avian influenza vaccine. The company's other pipeline candidates include mRNA vaccines for oncology and molecular therapies spanning tumors, liver, and ocular diseases.

CureVac NV Headlines

No Headlines